Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

on behalf of the SHP609-302 study group

doi:10.1016/j.ymgme.2023.107646

Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

on behalf of the SHP609-302 study group

Pediatrics

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The following text in the abstract incorrectly states the percentage of patients with at least one adverse event related to idursulfase-IT. ‘Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The text should read as follows. ‘Overall, 78.6% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The data are otherwise reported correctly in the article text and in Table 2. The authors would like to apologize for any inconvenience caused.

Original language	English (US)
Article number	107646
Journal	Molecular Genetics and Metabolism
Volume	140
Issue number	3
DOIs	https://doi.org/10.1016/j.ymgme.2023.107646
State	Published - Nov 2023

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
Genetics
Endocrinology

Access to Document

10.1016/j.ymgme.2023.107646

Fingerprint

Dive into the research topics of 'Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))'. Together they form a unique fingerprint.

Cite this

on behalf of the SHP609-302 study group (2023). Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016)). Molecular Genetics and Metabolism, 140(3), Article 107646. https://doi.org/10.1016/j.ymgme.2023.107646

on behalf of the SHP609-302 study group. / Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016)). In: Molecular Genetics and Metabolism. 2023 ; Vol. 140, No. 3.

@article{f4a6eb22fe894c09a815999c0b81e653,

title = "Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))",

abstract = "The following text in the abstract incorrectly states the percentage of patients with at least one adverse event related to idursulfase-IT. {\textquoteleft}Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT;{\textquoteright} The text should read as follows. {\textquoteleft}Overall, 78.6% of patients had at least one adverse event (AE) related to idursulfase-IT;{\textquoteright} The data are otherwise reported correctly in the article text and in Table 2. The authors would like to apologize for any inconvenience caused.",

author = "{on behalf of the SHP609-302 study group} and Joseph Muenzer and Burton, {Barbara K.} and Paul Harmatz and Guti{\'e}rrez-Solana, {Luis Gonz{\'a}lez} and Matilde Ruiz-Garcia and Jones, {Simon A.} and Nathalie Guffon and Michal Inbar-Feigenberg and Drago Bratkovic and Michael Hale and Yuna Wu and Yee, {Karen S.} and Whiteman, {David A.H.} and David Alexanderian",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = nov,

doi = "10.1016/j.ymgme.2023.107646",

language = "English (US)",

volume = "140",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "3",

}

on behalf of the SHP609-302 study group 2023, 'Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))', Molecular Genetics and Metabolism, vol. 140, no. 3, 107646. https://doi.org/10.1016/j.ymgme.2023.107646

Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016)). / on behalf of the SHP609-302 study group.
In: Molecular Genetics and Metabolism, Vol. 140, No. 3, 107646, 11.2023.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

AU - on behalf of the SHP609-302 study group

AU - Muenzer, Joseph

AU - Burton, Barbara K.

AU - Harmatz, Paul

AU - Gutiérrez-Solana, Luis González

AU - Ruiz-Garcia, Matilde

AU - Jones, Simon A.

AU - Guffon, Nathalie

AU - Inbar-Feigenberg, Michal

AU - Bratkovic, Drago

AU - Hale, Michael

AU - Wu, Yuna

AU - Yee, Karen S.

AU - Whiteman, David A.H.

AU - Alexanderian, David

PY - 2023/11

Y1 - 2023/11

N2 - The following text in the abstract incorrectly states the percentage of patients with at least one adverse event related to idursulfase-IT. ‘Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The text should read as follows. ‘Overall, 78.6% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The data are otherwise reported correctly in the article text and in Table 2. The authors would like to apologize for any inconvenience caused.

AB - The following text in the abstract incorrectly states the percentage of patients with at least one adverse event related to idursulfase-IT. ‘Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The text should read as follows. ‘Overall, 78.6% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The data are otherwise reported correctly in the article text and in Table 2. The authors would like to apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85166292060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166292060&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2023.107646

DO - 10.1016/j.ymgme.2023.107646

M3 - Comment/debate

C2 - 37517985

AN - SCOPUS:85166292060

SN - 1096-7192

VL - 140

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 3

M1 - 107646

ER -

on behalf of the SHP609-302 study group. Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016)). Molecular Genetics and Metabolism. 2023 Nov;140(3):107646. doi: 10.1016/j.ymgme.2023.107646

Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this